Apoptotic effects of salinomycin on human ovarian cancer cell line (OVCAR-3)

Kaplan, Fuat; Tekşen, Fulya

doi:10.1007/s13277-015-4212-6

Cited by 22 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They also indicated that the cause of apoptosis is related to activation of death receptor 5 (DR5) pathway, which was observed even at low doses of SAL (0.5 µM) [56]. In contrast, the Kaplan group observed induction of apoptosis by upregulation of CASP3 in OVCAR3 cell line even at 0.1 µM of SAL [57].…”

Section: Discussionmentioning

confidence: 99%

Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives—An In Vitro Study

et al. 2020

View full text Add to dashboard Cite

Polyether ionophore salinomycin (SAL) and its semi-synthetic derivatives are recognized as very promising anticancer drug candidates due to their activity against various types of cancer cells, including multidrug-resistant populations. Ovarian cancer is the deadliest among gynecologic malignancies, which is connected with the development of chemoresistant forms of the disease in over 70% of patients after initial treatment regimen. Thus, we decided to examine the anticancer properties of SAL and selected SAL derivatives against a series of drug-sensitive (A2780, SK-OV-3) and derived drug-resistant (A2780 CDDP, SK-OV-3 CDDP) ovarian cancer cell lines. Although SAL analogs showed less promising IC50 values than SAL, they were identified as the antitumor agents that significantly overcome the resistance to platinum-based drugs in ovarian cancer, more potent than unmodified SAL and commonly used anticancer drugs—5-fluorouracil, gemcitabine, and cisplatin. Moreover, when compared with SAL used alone, our experiments proved for the first time increased selectivity of SAL-based dual therapy with 5-fluorouracil or gemcitabine, especially towards A2780 cell line. Looking closer at the results, SAL acted synergistically with 5-fluorouracil towards the drug-resistant A2780 cell line. Our results suggest that combinations of SAL with other antineoplastics may become a new therapeutic option for patients with ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives—An In Vitro Study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…20 Studies by Kaplan and Teksen on the stable ovarian cancer cell line (OVCAR-3) demonstrated the activity of salinomycin: 40% of cells underwent apoptosis within 24 h of exposure. 21 A decrease was noted in the expression of the anti-apoptotic gene Bcl2.…”

Section: Salinomycinmentioning

confidence: 99%

Ovarian cancer stem cells: A target for oncological therapy

Markowska¹,

Sajdak²,

Huczyński³

et al. 2018

Adv Clin Exp Med

View full text Add to dashboard Cite

According to numerous studies, failures in treatment of ovarian cancer, i.e., a relapse and metastases, result from a small population of cancer stem cells (CSCs). They may also be responsible for tumor initiation. Cancer stem cells are resistant to chemo-and radiotherapy. Eradication of CSCs may involve the application of salinomycin, metformin and Clostridium perfringens; the effect of anti-angiogenic factors remains controversial. Salinomycin is an antibiotic isolated from Streptomyces albus bacteria. Its CSC-eradicating effect has been demonstrated both in ovarian cancer cell lines and in women with breast cancer. Clostridium perfringens enterotoxin (CPE) has been demonstrated to destroy CSCs in ovarian cancer both in vivo and in vitro. Metformin, apart from its hypoglycemic effect, reduces the CSC population and inhibits the proliferation of neoplastic cells and angiogenesis. Cancer stem cells with expression of VEGFR1+ have been described as affecting circulating cancer cells and influencing the formation of metastases. Both positive and negative effects of anti-angiogenic therapy on the CSC population have been documented.

show abstract

“…45 Salinomycin also acted on OVCAR-3 human ovarian cancer cells through caspase-mediated apoptosis without harming normal cells. 46 Recently, salinomycin demonstrated anti-angiogenic activity by VEGFR2 signaling pathway in gastric cancer xenografts. 47 …”

Section: Salinomycin As An Anticancer Agentmentioning

confidence: 99%

Salinomycin: A new paradigm in cancer therapy

2017

View full text Add to dashboard Cite

The primary hurdle in the treatment of cancer is acquisition of resistance by the tumor cells toward multiple drugs and selectively targeting the cancer stem cells. This problem was overcome by the chemotherapeutic property of recently discovered drug salinomycin. Exact mechanism of action of salinomycin is not yet known, but there are multiple pathways by which salinomycin inhibits tumor growth. Salinomycin decreases the expression of adenosine triphosphatebinding cassette transporter in multidrug resistance cells and interferes with Akt signaling pathway, Wnt/β-catenin, Hedgehog, and Notch pathways of cancer progression. Salinomycin selectively targets cancer stem cells. The potential of salinomycin to eliminate both cancer stem cells and therapy-resistant cancer cells may characterize the compound as a novel and an efficient chemotherapeutic drug.

show abstract

Apoptotic effects of salinomycin on human ovarian cancer cell line (OVCAR-3)

Cited by 22 publications

References 25 publications

Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives—An In Vitro Study

Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives—An In Vitro Study

Ovarian cancer stem cells: A target for oncological therapy

Salinomycin: A new paradigm in cancer therapy

Contact Info

Product

Resources

About